BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
Status:
Completed
Trial end date:
2018-07-26
Target enrollment:
Participant gender:
Summary
This was a multinational, multicenter, randomized, double-blind, placebo controlled study
with randomized withdrawal and retreatment, evaluating the safety and efficacy of
risankizumab 150 mg subcutaneous (SC) in participants with moderate to severe chronic plaque
psoriasis.